Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | FPR3 | P25089 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982017 | 0.89 | KDM4E (0.43) | KDM4ECYP2D6SMN1; SMN2HSD17B10CYP2C19 | |
| Cyclohexanol SCHEMBL9499915 | 0.82 | SMN1; SMN2 (0.45) | KDM4ECYP2D6SMN1; SMN2HSD17B10FPR3 | |
| SCHEMBL21172271 | 0.82 | KDM4E (0.45) | KDM4ECYP2D6SMN1; SMN2HSD17B10FPR3 | |
| SCHEMBL13463180 | 0.81 | KDM4E (0.43) | KDM4ECYP2D6SMN1; SMN2HSD17B10FPR3 | |
| SCHEMBL27837325 | 0.79 | KDM4E (0.41) | KDM4ECYP2D6SMN1; SMN2HSD17B10FPR3 | |
| SCHEMBL1979548 | 0.78 | SMN1; SMN2 (0.38) | KDM4ECYP2D6SMN1; SMN2HSD17B10CYP2C19 | |
| SCHEMBL6729276 | 0.78 | SMN1; SMN2 (0.38) | KDM4ECYP2D6SMN1; SMN2HSD17B10CYP2C19 | |
| SCHEMBL9501573 | 0.77 | KDM4E (0.40) | KDM4ECYP2D6SMN1; SMN2HSD17B10FPR3 | |
| SCHEMBL13037023 | 0.77 | KDM4E (0.40) | KDM4ECYP2D6SMN1; SMN2HSD17B10FPR3 | |
| SCHEMBL18569933 | 0.77 | MEN1 (0.43) | KDM4ECYP2D6SMN1; SMN2HSD17B10FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615537-B1 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| EP-4178574-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | Purdue Research Foundation (US) | 2023-05-17 | — | — | EP | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2023-03-14 | — | — | US | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| EP-3707138-B1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2014062636-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | WO | disclosed |
| US-8697706-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-15 | — | — | US | disclosed |
| US-8629150-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130095063-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055563-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013048995-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130078214-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | KDM4E 1873/4885CYP2D6 4510/4885SMN1; SMN2 2598/4885 |
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | KDM4E 2636/4885CYP2D6 2009/4885SMN1; SMN2 4857/4885 |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | KDM4E 2636/4885CYP2D6 2009/4885SMN1; SMN2 4857/4885 |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | KDM4E 3859/4885CYP2D6 12/4885SMN1; SMN2 1785/4885 |
| US-20080096861-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | KDM4E 3962/4885CYP2D6 4070/4885SMN1; SMN2 4801/4885 |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | KDM4E 2125/4885CYP2D6 637/4885SMN1; SMN2 4069/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | KDM4E 2559/4885CYP2D6 3256/4885SMN1; SMN2 3651/4885 |
| US-20130095063-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | KDM4E 4422/4885CYP2D6 300/4885SMN1; SMN2 2944/4885 |
| US-20130078214-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | KDM4E 4422/4885CYP2D6 300/4885SMN1; SMN2 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.